Recordati : Recordati trouve encore le moyen d’améliorer sa marge au S1
>Résultats S1 en hausse de 7% - Recordati a publié ses résultats du S1 2018 hier à la mi-journée. Les revenus ressortent à 696.1 M€, en hausse de 6.9% (T1, +7.2% / T2, +6.7%). La franchise des produits "Corporate" (1/3 des ventes) bénéficie d’une base de comparaison favorable avec l’acquisition de Seloken qui est consolidé depuis le 1er juillet 2017. Ainsi, la progression ressort à 33% sur le S1 (+4% hors Seloken). Soulignons que les ventes de Seloken (hypertension et...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.